Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methyladenosine SCHEMBL41422 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL278664 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL17124834 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512844 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18159462 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18512845 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL6934268 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL14075776 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL13403859 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL6725555 | 1.00 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5593 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705481-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705468-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | California Institute of Technology (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4632075-A2 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-10-15 | — | — | EP | claimed |
| US-20250304965-A1 | DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF | MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-10-02 | — | — | US | claimed |
| EP-4029522-B1 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | BioNTech SE (DE) | 2025-08-13 | — | — | EP | claimed |
| WO-2024233308-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20240366793-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INST OF TECHN (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024229296-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-11-07 | — | — | WO | claimed |
| CN-118773192-A | Oligonucleotide and composition thereof | 力赛新(广东)制药有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-20240229075-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-07-11 | — | — | US | claimed |
| CN-101316606-A | Methods and pharmaceutical compositions for treating and preventing hepatitis C infection | SCYNEXIS INC (US) | 2008-12-03 | — | — | CN | claimed |
| EP-1948822-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2008-07-30 | — | — | EP | claimed |
| US-20070231810-A1 | Multicomponent nucleic acid enzymes and methods for their use | SPEEDX PTY LTD (AU) | 2007-10-04 | — | — | US | claimed |
| WO-2007041774-A1 | MULTICOMPONENT NUCLEIC ACID ENZYMES AND METHODS FOR THEIR USE | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2007-04-19 | — | — | WO | claimed |
| EP-1539188-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | claimed |
| US-20030007961-A1 | Orthomolecular vitamin E derivatives | WILBURN MICHAEL D (US) | 2003-01-09 | — | — | US | claimed |
| WO-2002057425-A2 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | claimed |
| EP-0795029-A1 | CHEMICAL LABELLING OF OBJECTS | Pabio (NO) | 1997-09-17 | — | — | EP | claimed |
| CN-1148811-A | Compound having antihypertensive, cardioprotective, anti-ischemic and antilipolytic functions | RHONE POULENC RORER PHARMA (US) | 1997-04-30 | — | — | CN | claimed |
| WO-1996017954-A1 | CHEMICAL LABELLING OF OBJECTS | PABIO (DK) | 1996-06-13 | — | — | WO | claimed |